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ABSTRACT 
 CXCL16 is an interferon-inducible chemokine of the CXC-subfamily and functions as an 
adhesion molecule, when membrane bound, and a chemoattractant when soluble. Upregulation 
of cell associated CXCL16 (cCXCL16) in colorectal cancer is associated with increased tumor 
infiltrating lymphocytes and good prognosis. ADAM10 and ADAM17 are metalloproteinases 
responsible for cleaving CXCL16, releasing soluble CXCL16 (sCXCL16) and contributing to 
proliferation and migration of mesangial cells, in kidney inflammatory disease. We hypothesize 
that cCXCL16 is a substrate for ADAM10 and ADAM17 cleavage in colorectal cancer, releasing 
sCXCL16, which mediates cell proliferation. To this end, we first identified CXCL16 in the 
human colon carcinoma cell line, RKO, by immunohistochemistry. cCXCL16 was found in the 
membrane, cytoplasm and nucleus. We treated RKO, in vitro, with an inflammatory cytokine 
mix containing 1.4 nM rhIFNγ, 2.0 nM rhTNFα and 2.0 nM rhIL1β to increase the cleavage of 
cCXCL16 to sCXCL16. Overnight incubation with the cytokine mix significantly (P=.004) 
increased the release of sCXCL16 compared to normal conditions. To confirm that a 
metalloproteinase is responsible for the cleavage of cCXCL16, we used a broad spectrum 
metalloproteinase inhibitor, GM6001, in combination with inflammatory stimulation, in cell 
culture. We assayed the supernatant using ELISA for sCXCL16. GM6001 at 100 µM decreased 
sCXCL16 to levels indistinguishable from the background. Using siRNA, we knocked down the 
expression of ADAM10 and ADAM17, independently, to determine if the activity of each on 
cCXCL16 was mediated by inflammatory stimulation. It was shown that ADAM10 
constitutively cleaved cCXCL16, and ADAM17 cleavage activity was induced by inflammatory 
stimulation. To determine if sCXCL16 increased colorectal cancer cell (CRC) proliferation 
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through ligand-receptor binding, we treated cells with a range of rhCXCL16 from 3.125-100 
ng/mL. rhCXCL16 did not increase RKO proliferation at doses up to 100 ng/mL. We used 
GM6001, to inhibit the cleavage of cCXCL16 into sCXCL16 then performed an ATPase assay 
and 6 day cell cycle analysis, under inflammatory stimulation. Increased cleavage of cCXCL16 
induced by inflammatory stimulation with the cytokine mix containing 1.4 nM rhIFNγ, 2.0 nM 
rhTNFα and 2.0 nM rhIL1β, increased RKO proliferation and reduced apoptosis. We conclude 
that ADAM10 and ADAM17 cleavage of cCXCL16 to sCXCL16 is increased by ADAM17 
activation with inflammatory stimulation. The cleavage of the extracellular portion from 
cCXCL16 is associated with increased proliferation and decreased apoptosis of colorectal cancer 
cells. 
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INTRODUCTION 
Inflammation marks the transition between the innate and adaptive immune response, when 
macrophages and neutrophils secrete cytokines and chemokines responsible for moderating 
cellular activities and recruiting cells expressing the appropriate receptors 
1
. Antigen presenting 
cells (APCs) travel back to lymph nodes and the splenic red pulp where B cells are activated and 
T cells expressing antibodies specific to peptides found on the surface of APCs, are cloned. 
Inflammation has been associated with cancer since Virchow observed leukocytes in neoplastic 
tissue 150 years ago 
2
. These tumor infiltrating leukocytes are recruited through ligand-receptor 
interactions directed by chemokine gradients In 2003, it had been determined that almost 25% of 
all cancer cases worldwide were attributable to chronic infection and inflammation, according to 
B. Stewart and P. Kleihues World Cancer, Report (2003). CXCL16 is an inflammatory 
chemokine and known participant in the transition between the innate and adaptive immune 
response by recruiting CD4
+
, CD8
+
 T cells and NKT cells, which express the cell surface 
receptor CXCR6 
3, 4
.The known biological functions of CXCL16 appear to be mitigated by post-
translational proteolytic processing. While expressed as a membrane-bound protein, CXCL16 
acts as an adhesion molecule, forming tight junctions through ligand-receptor binding. In this 
manner, CXCL16 expressed on dendritic cells supports the adhesion of T cells in splenic red 
pulp 
5
. After cell surface shedding into soluble form, CXCL16 is chemotactic for cells involved 
in the immune response, vascular endothelial cells 
6
 and human mesangial cells 
7
, expressing 
CXCR6. CXCL16 has been found up-regulated in inflammatory disease and cancer and 
positively correlated to increased leukocyte trafficking, aggressiveness and metastasis of tumor 
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cells
7
 
4, 8-10
. Cell associated CXCL16 has been associated with good prognosis and increased 
tumor infiltrating lymphocytes in colorectal cancer 
4
suggesting that CXCL16 expression may be 
prognostic for patient survival; however the role of CXCL16 in cancer progression is not fully 
understood. 
 ADAM10 and ADAM17 are α-secretases that shed cell surface molecules by proteolytic 
cleavage. This cleavage releases c-terminal fragments (CTFs) that are further processed by β- 
and γ-secretases. ADAM10 and ADAM17 shed CXCL16 from the cell membrane into the 
soluble form releasing CTFs of unknown function
11
. In some inflammatory proliferative diseases 
and cancers the sheddase activity of ADAM10 and ADAM17 on CXCL16, specifically, has been 
linked to increased tumor cell invasiveness and migration, as well as T cell chemotaxis, 
proliferation, and migration
7, 8, 10
. In addition, CXCL16 promotes chemotaxis, proliferation and 
tube formation in human vascular endothelial cells
6
. Cell associated CXCL16 has been shown to 
decrease and inhibit proliferation in human mammary and colon carcinomas and pancreatic 
ductal adenocarcinomas, whereas soluble CXCL16 (sCXCL16) has been shown to increase 
proliferation
10, 12
. Inhibiting the expression of CXCL16, ADAM10 and ADAM17 has been 
shown to arrest mesangial cell proliferation under inflammatory stimulation
7
.  
Stimulation of pancreatic ductal cells with exogenous sCXCL16, under normal 
conditions, does not increase cell proliferation
10
. Also, inhibiting the expression of CXCL16, 
ADAM10 and ADAM17 or CXCL16 alone, under normal conditions, does not significantly 
affect proliferation
7
. Mouse colon cancer cells already expressing CXCL16 do not show a 
notable increase in proliferation when stimulated with exogenous sCXCL16
12
. These data 
suggest that the function of CXCL16 in cancer cell proliferation, under inflammatory 
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stimulation, is determined by the shedding of sCXCL16 from the cell membrane. Therefore, we 
tested ADAM10 and ADAM17 sheddase activity as a mediating event in human colon cancer 
cell proliferation, using in vitro studies with the human colon cancer cell line RKO. Our results 
suggest that the increase in colon cancer cell proliferation is not the result of autocrine signaling 
through ligand-receptor binding of sCXCL16, but through intercellular signaling by the CTF also 
released by ADAM10 and ADAM17 shedding. The release of sCXCL16 has the added effect of 
decreasing apoptosis. Our data suggest that CXCL16 may be a novel target for reducing 
proliferation and increasing apoptosis in colon cancer. 
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MATERIALS AND METHODS 
Identification of cell-associated CXCL16 
Materials 
Human colon carcinoma cell line, RKO, was purchased from ATCC, and cultured in 
vented cap T-75 tissue culture flasks (NUNC) in EMEM supplemented with 10% heat 
inactivated FBS (GIBCO/Life Technologies) and 1% Penicillin-Streptomycin (GIBCO/Life 
Technologies) in a humidified incubator with 5% CO2 at 37˚ C. Cells expressing CXCL16 were 
identified by ICC using an anti CXCL16 (C-20) goat polyclonal IgG antibody (Santa Cruz). 
Immunocytochemistry was performed on cells fixed to precleaned glass microscope slide cover 
slips (VWR) using 4% paraformaldehyde solution. 
Reagents and solutions 
4% Paraformaldehyde solution 
 While 80 mL of autoclaved distilled water was heated to 60⁰C, 4 grams of 
paraformaldehyde was added as solution stirred. The solution was covered and allowed to come 
up to temperature. 10 N NaOH was added drop wise until solution cleared: approximately 10 
drops. 4 mL of 25X PBS was added to bring volume to 100 mL. pH was adjusted to 7.0 using 
HCl. Solution was sterilized using vacuum filtration and stored in a light sensitive bottle. 
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Peroxidase quencher 
 Peroxidase quencher was made in PBS with a final concentration of 3% peroxide and 1% 
sodium azide. 
PBST 
 2 mL Tween-20 was dissolved in 800 mL PBS. The pH was adjusted to 7.2, and then the 
solution was autoclaved. 
SDS 
 .5 grams SDS was added to 50 mL PBS and the solution was stirred until clear. 
10% BSA 
 5 grams of BSA was dissolved in PBS to a final volume of 50 mL. 
0.1% LiCO3 
 .05 grams of LiCO3 was dissolved in 50 mL autoclaved distilled water. 
Fixed cell preparation 
  250,000 cells were plated on glass cover slips placed in each well of a 6 well plate. Cells 
were grown to confluence in 2 mL EMEM full growth media until cells reached confluence. 
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Immunocytochemistry 
 All steps were performed with cover slips in 6 well plates. Full growth media was 
removed and cells were washed and incubated for 1 minute; two times with ice cold PBS. Cells 
were fixed for 10 minutes in 1 mL of 4% paraformaldehyde, then washed and incubated for 2 
minutes; three times with PBST. Cells were then dehydrated by 5 minute incubations with 
increasing concentrations of methanol (25%, 50%, 75% and 100%). Antigen retrieval was 
performed by washing fixed cells three times, in PBS for 5 minutes each, then incubating in 1% 
SDS for 5 minutes and finally washing three times for 5 minutes in PBS. Peroxidase activity was 
quenched with a 15 minute incubation in peroxidase quencher. Fixed cells were blocked in 10% 
BSA for 30 minutes, and then blocking agent was removed. Cells were incubated for one hour at 
room temperature in primary antibody specific for an epitope on the internal portion of CXCL16 
(Santa Cruz) at a 1:50 concentration. Primary antibody was removed after one hour and cells 
were washed three times for five minutes in PBS. Cells were incubated for 1 hour at room 
temperature in secondary antibody, anti-goat-HRP (Santa Cruz) at a 1:100 concentration. 
Secondary antibody was removed after one hour and cells were washed three times for 5 minutes 
in PBS Color was developed with a 5 minute incubation in DAB. After incubation cells were 
washed 2 times in tap water. Counter staining was performed with a 5 minute incubation in 
hematoxylin. After incubation the hematoxylin solution was removed. The cells were washed 
two times in tap water, dipped in 3% acid-alcohol (Sigma), washed one time in tap water then 
dipped in LiCO3. Fixed cells were then dehydrated by incubating for three times in 100% 
methanol for 5 minutes then incubating three times in 100% xylene for 5 minutes. Glass cover 
slips were mounted on precleaned glass microscope slides (Fisher Scientific). Digital images 
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were taken using a camera (Leica DFC300 FX) mounted on a light microscope (Nikon Eclipse 
E400). 
Induced increase in soluble CXCL16 in cell culture 
Materials 
The inflammatory cytokine mix 
7
 containing 1.4 nM rhIFNγ (R & D Systems), 2 nM 
rhTNFα (R & D Systems) and 2 nM rhIL1β (R & D Systems). Conditioned media was assayed 
for soluble CXCL16 using a premade Quantikine Human CXCL16 ELISA kit (R & D Systems), 
according to the manufacture’s instructions.  
Cell culture preparation 
RKO cells were plated in 100 cm tissue culture dishes (BD Biosciences) at the 
concentration of 4 million cells in 5 mL of full growth media. The cells were allowed to adhere 
in a humidified incubator with 5% CO2 at 37˚C overnight. After incubation the media was 
removed, the cells were washed two times with DPBS, and the media was changed to include the 
inflammatory cytokine mix (1.4 nM rhIFNγ, 2 nM rhTNFα and 2 nM rhIL1β). Cells were 
allowed to incubate in a humidified incubator with 5% CO2 at 37˚C for either 15 minutes or 
overnight. Control cells were plated, incubated 15 minutes or overnight in full growth media that 
did not include the inflammatory cytokine mix. After incubation, the conditioned media was 
removed, centrifuged to remove any debris then assayed for soluble CXCL16. 
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ELISA 
 All samples were assayed in quadruple. A Quantikine Human CXCL16 ELISA was 
purchased from R & D Systems (Minneapolis, MN). All buffers and reagents were brought to 
room temperature before assay was performed. The CXCL16 standard was reconstituted with 1 
mL autoclaved distilled water to a stock concentration of 100 ng/mL. Serial dilutions were made 
using the provided Calibrator Diluent RD5R to final working concentrations of 10 ng/mL, 5 
ng/mL, 2.5 ng/mL, 1.25 ng/mL, 0.625 ng/mL, 0.315 ng/mL and 1.156 ng/mL. The Calibrator 
Diluent was used as the zero standard. 100 mL of the provided 100µl Assay Diluent RD1W was 
added to each well. 50 µl of each standard and sample was added to individual wells. After 2 
hours incubation at room temperature, the solutions were removed and the wells were washed 
four times with 300 µl of the provided wash buffer. After the fourth wash 200 µl of the provided 
conjugate was added to each well and incubated for two hours at room temperature. After the 
incubation the solutions were removed and the plate was washed four times with 300 µl of the 
provided wash buffer. After the fourth wash 200 µl of the provided substrate solution was added 
to each well in incubated for 30 minutes at room temperature protected from light. After the 
incubation 50 µl of the provided stop solution was added to each well and the absorbance 
intensity was read using a microplate reader (FLUOstar OPTIMA). 
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Optimization of GM6001 broad spectrum metalloproteinase inhibitor 
Materials 
 The broad spectrum metalloproteinase inhibitor, GM6001 (Sigma) was used to 
inhibit ADAM10 and ADAM17 proteolytic activity. The inflammatory cytokine mix containing 
1.4 nM rhIFNγ (R & D Systems), 2 nM rhTNFα (R & D Systems) and 2 nM rhIL1β (R & D 
Systems) was used to sCXCL16 concentrations in the cell culture supernatant. Conditioned 
media was assayed for soluble CXCL16 using a premade Quantikine Human CXCL16 ELISA 
kit (R & D Systems), according to the manufacture’s instructions.  
Determining sCXCL16 concentration using ELISA 
 250,000 RKO cells were plated in 6 well plates in full growth media and incubated 
overnight in a humidified incubator at 37˚C in 5% CO2, to allow cells to adhere. After 
incubation, the media was removed and the cells were washed 2 times with DPBS. Cultures were 
then incubated in increasing concentration of GM6001 (Sigma): 25 µM, 50 µM, 100 µM, 200 
µM and 400µM for 15 minutes, then 2 mL of full growth media with the addition of the 
inflammatory cytokine mix was added to the wells and the plates were incubated overnight in a 
humidified incubator at 37˚C in 5% CO2. After incubation, culture media was removed and 
centrifuged to remove debris and assayed for sCXCL16 using a premade Quantikine Human 
CXCL16 ELISA kit (R&D Systems) as previously described. All conditions were performed in 
triplicate. All samples were assayed in duplicate. 
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Determining the role of ADAM10 and ADAM17 in cCXCL16 cleavage into sCXCL16 
Materials 
 siRNA duplexes were purchased from Invitrogen (Carlsbad, CA). The sequences are as 
follows: ADAM10 5’ AGA CAU UAU GAA GGA UUA UTT 3’; ADAM17 5’ GAG AAG 
CUU GAU UCU UUG CTT 3’; and a scrambled control 5’ AGG UAG UGU AAU GCG CUU 
GTT 3’. Cells were tranfected using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions and using electroporation with a GenePulser Xcell with Shockpod 
(BioRad).  
Optimization of knockdown 
500,000 cells were treated with differing concentrations of siRNA duplexes. 
Transfections were carried out using Lipofectamine 2000 (Invitrogen). Different picomole 
concentrations of siRNA were diluted in 25 µl of Opti-MEM I Medium, and mixed gently. 10 µl 
of Lipofectamine 2000 was diluted into 25 µl of Opti-MEM I Medium (Invitrogen) and 
incubated at room temperature for 5 minutes. After incubation, the diluted Lipofectamine 2000 
was added to 6 well plates with the diluted RNAi complexes, mixed gently, and incubated for 15 
minutes at room temperature. After incubation, cells were added to the well and the media 
volume was brought up to 1 mL using Opti-MEM I Medium. Cells were incubated overnight in a 
humidified incubator at 37˚C with 5% CO2. After overnight incubation, the media was removed, 
the cells were washed 2 times with DPBS and 1 mL of EMEM full growth media was added. 
After overnight incubation in a humidified incubator at 37˚C with 5% CO2 the media was 
11 
 
collected for use in ELISA. This procedure was repeated with the exception that cells were 
transfected by electroporation at 300V and 960µF with a GenePulse Xcell (BioRad). ELISA was 
performed on cell culture supernatant to assay for sCXCL16 using a premade Quantikine Human 
CXCL16 ELISA kit (R&D Systems) as previously described. Effective knockdown was 
determined through RNA analysis using qRT-PCR of cDNA reverse transcribed from tcRNA 
extracted from cell pellets. 
sCXCL16 after ADAM10/ADAM17 knockdown under non-inflammatory and 
inflammatory conditions 
 500,000 cells for each condition were electroporated at 300V and 960µF with 
predetermined concentrations of siRNA duplexes for ADAM10, ADAM17 and equivalent 
concentration of scramble siRNA duplexes. Cells were plated in 6 well plates in 1 mL media and 
incubated overnight in a humidified incubator at 37˚C with 5% CO2. After overnight incubation, 
the media was removed, the cells were washed 2 times with DPBS and 1 mL of fresh media was 
added. This procedure was repeated with the addition that the fresh media contained the 
inflammatory cytokine mix including: 1.4 nM rhIFNγ (R & D Systems), 2 nM rhTNFα (R & D 
Systems) and 2 nM rhIL1β (R & D Systems). Each condition was plated in triplicate. sCXCL16 
was quantified using a premade Quantikine Human CXCL16 ELISA kit (R & D Systems) as 
previously described. Knockdown was determined using qRT-PCR, as previously described. 
Wild type RKO cell culture was used as a control. GAPDH was used as the endogenous gene 
expression control.  
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Comparison of proliferation in sCXCL16 versus cCXCL16 
Materials 
 Proliferation was measured using the ATPase assay, Cell Titer Glo (Promega). 
Luminescence intensity was measured using a microplate reader (FLUOstar OPTIMA). GM6001 
(Sigma) was used to inhibit ADAM10 and ADAM17 activity to increase cCXCL16. 
Growth curve for optimal plating density 
 RKO cells were plated, in quadruple, in white walled 96 well plates (Lonza) at 500 
cells/well, 1500 cells/well, 4500 cells/well, 13,500 cells/well and 40,500 cells/well, in 100 µl of 
full growth media. Each cell concentration was plated for a reading at a 0 time point to establish 
a baseline, 2 days, 4 days and 6 days. 100 µl of reconstituted cell titer glo reagent was added to 
each well and incubated protected from light at room temperature to ensure complete lysis and 
allow optimal luminescence intensity. The plate was incubated in a humidified incubator at 37˚C 
in 5% CO2 in between time points. 
Measuring the effect of cCXCL16 on proliferation 
 EMEM full growth media was made including 100 µM GM6001. Cells were trypsinized 
from culture, pelleted and resuspended in 1 mL DPBS with the addition of 100 µM GM6001, 
allowed to sit for 15 minutes then counted. 1000 cells were plated in wells of a 96 well plate 
using 100 µl of full growth media containing 100µM GM6001. Full growth media containing 
GM6001 was plated without cells as a background luminescence control. 100 µl of cell titer glo 
13 
 
reagent was added to the wells then incubated for 15 minutes at room temperature. 
Luminescence was quantified on a microplate reader (FLUOstar OPTIMA). Each experimental 
condition was plated in triplicate. Each condition was assayed on days 1 - 7. These experimental 
conditions were repeated with the additional treatment of the inflammatory cytokine mix. 
Measuring the effect of sCXCL16 on proliferation 
 Cells were trypsinized from culture, pelleted, resuspended in 1 mL DPBS and counted. 
1000 cells were plated in wells of a 96 well plate using 100 µL of full growth media. Full growth 
media was plated without cells as a background luminescence control. 100 µl of cell titer glo 
reagent was added to the wells then incubated for 15 minutes at room temperature. 
Luminescence was quantified on a microplate reader (FLUOstar OPTIMA). Each experimental 
condition was plated in triplicate. Each condition was assayed on days 1 - 7. These experimental 
conditions were repeated without the additional treatment of the inflammatory cytokine mix.  
Measuring the effect of exogenous sCXCL16 on proliferation 
 Aliquots of EMEM full growth media including 100 µM GM6001 were made with the 
following concentration of rhCXCL16 to simulate stimulation of cells by exogenous soluble 
CXCL16: 3.125 ng/mL, 6.25 ng/mL, 12.5 ng/mL, 25 ng/mL, 50 ng/mL and 100 ng/mL. One 
aliquot contained no rhCXCL16 for use as a control. Cells were trypsinized from culture, 
pelleted and resuspended in 1 mL DPBS with the addition of 100 µM GM6001, allowed to sit for 
15 minutes then counted. 1000 cells were plated in wells of a 96 well plate using 100 µl of the 
media aliquots containing rhCXCL16 100 µl of media only was plated as a background control. 
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100 µl of cell titer glo reagent (Promega) was added to the wells then incubated for 15 minutes at 
room temperature. Luminescence was quantified on a microplate reader (FLUOstar OPTIMA). 
Each experimental condition was plated in triplicate. Each condition was assayed on days 1 – 7. 
Determining the effect of sCXCL16 vs. cCXCL16 on proliferation and apoptosis under 
inflammatory conditions 
Materials 
 FACS Caliber (BD Biosciences) was used to perform the cell cycle analysis 
Reagents and solutions 
PI stain 
 To make 50 mL, 59 mg sodium citrate, 2.5 mg propidium iodide and 50 µl Triton X were 
mixed. Autoclaved deionized water was added for a total volume under 50 mL. The solution was 
brought to pH 7.8 and then 150 µl of RNase 1was added. Autoclaved deionized water was added 
to a total volume of 50 mL. 
Staining protocol 
 Cells were fixed in 70% ethanol. After fixing, cells were washed in PBS and PI stain was 
added in the dark while vortexing. 
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Proliferation under inflammatory stimulation determined by ATPase assay 
 1,000 cells were plated in wells of a 96 well plate in 100 µl of EMEM full growth media 
with the addition of the inflammatory cytokine mix containing: 1.4 nM rhIFNγ (R & D Systems), 
2 nM rhTNFα (R & D Systems) and 2 nM rhIL1β (R & D Systems). Cells were incubated for 15 
minutes with the metalloproteinase inhibitor, GM6001, and then plated in wells of a 96 well 
plate in 100µl of EMEM full growth media with the addition of GM6001 and the inflammatory 
cytokine mix. Full growth media and full growth media with GM6001 were plated with no cells 
for use as a background luminescence control. For 6 days proliferation was determined by 
adding 100 µl of cell titer glow reagent, allowing the cells to incubate at room temperature for 15 
minutes and reading luminescence intensity with a microplate ready (FLUOstar OPTIMA). Each 
condition was read daily for 6 days. 
Apoptosis analysis under inflammatory stimulation determined by cell cycle analysis 
 1 million cells were plated in each well in a 6 well plate with EMEM full growth media 
with the addition of the inflammatory cytokine mix containing: 1.4 nM rhIFNγ (R & D Systems), 
2 nM rhTNFα (R & D Systems) and 2 nM rhIL1β (R & D Systems). Cells were incubated in a 
humidified incubator at 37˚C with 5% CO2. Cells were trypsinized and collected for PI staining 
and cell cycle analysis by flow cytometry, every day for 6 days, using a FACS Caliber (BD 
Biosciences) The experimental conditions were repeated with the addition of the 
metalloproteinase inhibitor, GM6001. 
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RESULTS 
CXCL16 expression in RKO 
CXCL16 is one of two known chemokines which have a membrane bound form 
functioning as a strong adhesion molecule for cells expressing the receptor, CXCR6 
5
. 
Ectodomain shedding produces a soluble form of CXCL16 which is a strong chemoattractant 
11
. 
CXCL16 was identified in the Colo205, LS174T, SW480, and T84 colon cancer cell lines as 
well as human tissues resected from colon tumors by RT-PCR and immunohistochemistry using 
an antibody recognizing an unidentified epitope 
1
. In this study, the transcription of CXCL16 in 
human tumor samples was compared to transcription in the normal mucosa, grouped as weak, 
intermediate and strong expressers using staining intensity with immunohistochemistry. 
Transcription levels were then compared to staining intensity of CD4 
+
and CD8 
+
 tumor 
infiltrating lymphocytes. Colon tumor cells had higher transcription of CXCL16 than normal 
mucosa and the CXCL16-strong stain intensity group had a higher incidence of TIL (tumor 
infiltrating lymphocytes). CXCL16 was found to be associated with the cell membrane and the 
cytoplasm. CXCL16 was also identified in a sample of 23 human rectal patients using RT-PCR, 
western blotting and immunohistochemistry using an antibody recognizing an epitope on the 
chemokine domain. These data showed no significant difference in transcription between tumor 
cells and normal cells of the same patient, and western blotting and immunohistochemistry 
showed decreased CXCL16 in tumor tissue and lysate compared to the normal tissue of the same 
patient
16
. 
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We wanted to determine if CXCL16 was expressed in the human colon cancer cell line 
RKO. Understanding that CXCL16 is shed from the cell membrane, we used an antibody 
targeting an epitope in the cytoplasmic domain. γ-secretases process the surface molecules, 
Notch and E-Cadherin , which generate C-terminal fragments functioning as signal transmitters 
11
. C-terminal fragments of CXCL16 have been found in the normal embryonic kidney cell line, 
HEK293 
11
, suggesting that CXCL16 may require similar processing for functional activation or 
perform a similar functional role as Notch or E-Cadherin. To further elucidate the potential for 
CXCL16, not just as an adhesion molecule and soluble chemoattractant, but possibly as an 
intracellular signaling molecule, we performed immunocytochemistry on RKO cells fixed to 
glass cover slips, with an anti-CXCL16 antibody targeting a cytoplasmic epitope, to identify the 
areas of the cell containing CTFs (c-terminal fragments) of CXCL16.  
We identified CXCL16 on the cell membrane, in the cytoplasm, and in the nucleus of 
RKO cells, as indicated by red staining (Figure 1). Protein that has performed its function or is 
nonfunctional is normally targeted for degradation. These data suggest that the C-terminal 
fragments of CXCL16 may perform a functional role in colorectal tumor cells. Due to the 
identification of CXCL16 in RKO further studies are possible.  
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Figure 1. Immunocytochemistry of RKO cells stained using anti-CXCL16 antibody. 
CXCL16 can be found associated with the cell membrane, cytoplasm and nucleus of RKO 
cells in culture. 
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Inflammatory stimulation increases sCXCL16 
 Treating cells in vitro with inflammatory stimulation including TNFα and IFNγ increases 
the release of sCXCL16 in astrocytes, glioma cells, endothelial cells from human umbilical vein 
and smooth muscle cells, and human mesangial cells
7, 8, 17
. To determine if CXCL16 is shed from 
the membrane of human colorectal cells, we treated RKO cells with a cytokine mix containing 
2.0 nM IL-1β, 2.0 nM TNFα and 1.4 nM IFNγ 7. We used two incubation times to determine if 
sCXCL16 increased over time under constant stimulation. We used ELISA to test the 
concentration of CXCL16 in the cell culture supernatant after an incubation of 15 minutes and 
overnight incubation. Soluble CXCL16 increases with stimulation in as little as 15 minutes after 
the initial assault, however there was a significant increase of sCXCL16 (P=.004) compared to 
the unstimulated control after overnight stimulation (<24 hr) (Figure 2). CXCL16 is an IFNγ –
inducible chemokine, which suggests that inflammatory stimulation would increase the 
transcription of CXCL16 making more available for sheddase activity. However, post-
transcriptional modifications, evidenced by the shedding of CXCL16, may be induced by this 
same mechanism. Understanding the transcriptional and post-transcriptional mechanisms 
involved when inflammatory stimulation increases sCXCL16 may suggest one or more targets to 
mediate this activity. 
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Figure 2. sCXCL16 concentrations in RKO cell culture supernatants after 15 minute or 
overnight (OV) incubations with the inflammatory cytokine mix containing 1.4 nM rhIFNγ, 
2.0 nM rhTNFα and 2.0 nM rhIL1β. ELISA was performed to measure the amount 
(pg/mL) of sCXCL16 in RKO cell supernatant. 
 
* indicates P=.004 using Welch’s t-test between the control and overnight cell culture 
populations. 
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GM6001 optimal biological dose as determined by ELISA 
 ADAM10 and ADAM17 are responsible for shedding of CXCL16 in human mesangial 
cells 
7
. To investigate the role of ADAM10 and ADAM17 on the shedding of CXCL16 in human 
colorectal cancer cells we confirmed that shedding of CXCL16 is achieved through 
metalloproteinase activity. GM6001,a broad spectrum metalloproteinase inhibitor, obtained 
lyophilized from Sigma, inhibits proteolysis of some metalloproteinases, including ADAM10 
and ADAM17 
7
. To measure the efficacy of GM6001 to inhibit metalloproteinase cleavage of 
cCXCL16 into sCXCL16 on RKO, cells were incubated with GM6001, reconstituted in DMSO, 
with concentrations ranging from 25 µM to 400 µM under inflammatory stimulation. After an 
initial 15 minute incubation in GM6001, cells were cultured overnight in media including 
GM6001 with the addition of inflammatory cytokine stimulation. The supernatants were 
collected and assayed for sCXCL16 concentrations using ELISA. Full growth media was used as 
a control to identify baseline absorbance. GM6001 at 100 µM was determined to be optimal for 
metalloproteinase inhibition by causing a decrease in sCXCL16 to levels indistinguishable from 
background absorbance levels (Figure 3). Although higher doses of inhibitor, up to 400 µM 
concentration, showed a trend in decreased detectable levels of sCXCL16, this also increased the 
volume of DMSO introduced into cell culture, thereby increasing the risk of toxicity to the cells. 
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Figure 3. sCXCL16 concentrations in cell culture supernatants as determined by ELISA. 
RKO cells were incubated overnight in full growth media in the presence of GM6001 (25 
µM - 400µM) and inflammatory stimulation with 1.4 nM rhIFNγ, 2.0 nM rhTNFα and 2.0 
nM rhIL1β. 
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ADAM10 is responsible for constitutive shedding of sCXCL16 
 ADAM10 has been associated with the constitutive cleavage of cell membrane adhesion 
molecules including CXCL16 
17
 
18
and ADAM17 has been associated with inflammatory induced 
cleavage 
8, 17
 To determine the roles of ADAM10 and ADAM17 in shedding CXCL16 from 
RKO cells we knocked down the expression of each metalloproteinase with siRNA 
oligonucleotides targeting ADAM10 (labeled A10) and ADAM17 (labeled A17). Control cells 
were transfected with scrambled oligonucleotides in concentrations comparable to those used for 
ADAM10 and ADAM17, 750 pmol/mL (SCR 750) and 1500 pmol/mL (SCR 1500), 
respectively. We measured CXCL16 proteolysis using sandwich ELISA targeting sCXCL16 in 
the cell culture media. We assayed the degree of knockdown by qRT-PCR with primers specific 
for ADAM10 and ADAM17 then determined the percentage of gene expression as compared to 
the control using the formula 100 – [(1-2-ΔΔCT) x 100]. After overnight incubation without 
inflammatory stimulation the knockdown of ADAM10 decreased sCXCL16 to levels 
indistinguishable from background absorbance levels, although ADAM17 was still being 
expressed (Figure 4 A). ADAM10 expression was 38.6% of the control expression level (Figure 
4 C). Under non-inflammatory conditions ADAM17 expression was knocked down to 44.34% of 
control levels, as ADAM10 continued to be expressed (Figure 4 C). Although the level of knock 
down for ADAM17 was similar to that shown for the independent knock down of ADAM10, the 
decrease of sCXCL16 was not comparable to that in the ADAM10 knockdown experiment, as 
shown in Figure 4 A. These data suggest that under non-inflammatory conditions ADAM10 
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sheddase activity is necessary and sufficient to account for sCXCL16 in comparison to 
ADAM17.  
Although we attempted to repeat these studies under inflammatory conditions, we did not 
achieve the level of knockdown for either ADAM10 (2%) or ADAM17 (24%), (Figure 4 D), 
compared to the scrambled controls, SCR 750 and SCR 1500, respectively. It is possible that 
inflammatory conditions induce the transcription of ADAM10 and ADAM17 at a rate which 
overwhelmed the siRNA ability to induce degredation of the mRNA. However, the slight 
decrease in sCXCL16, as shown in Figure 4 B, suggests that ADAM17 does participate in 
shedding sCXCL16 under inflammatory conditions. These data suggest that ADAM10 
constitutive cleavage is not sufficient to account for all sCXCL16 released under inflammatory 
conditions. 
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Figure 4. sCXCL16 concentrations in cell culture supernatants determined by ELISA after 
siRNA-knockdown of ADAM10 or ADAM17 under normal (A) and inflammatory (B) 
stimulation. Percent (%) expression compared to the controls were determined by qRT-
PCR of mRNA levels after knockdown as determined by the formula 1-[(1-2
-ΔΔCT
)x100] 
under normal (C) and inflammatory (D) stimulation. 
Student t-test determined there is no significant difference in sCXCL16 concentrations 
between experimental conditions and control P > 0.05. 
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Optimal plating density for RKO cells 
 To identify the effect of CXCL16 on the proliferation of RKO cells, we measured cell 
viability as determined by ATP concentration. Increased ATP levels suggest increased cellular 
metabolic activity and cell number. However, limiting factors for cells in culture include growth 
factor and nutrient resources, as well as growth surface area, as many cells maintain contact 
inhibition. We tested for the optimal plating density for RKO cells in 96 well plates to ensure the 
results of our proliferation studies were not biased due to the limiting factors named above. Cells 
were plated at the lowest density of 500 cells up to 40,500 cells. Cells were cultured in 100 µl 
full growth media, with no media changes for one week. We determined the optimal plating 
density to be between 50 and 1500 cells per well (Figure 5). Cell culture concentrations of 1000 
cells per well in a 96 well plate would allow for testing of inflammatory stimulation on 
proliferation, over five days, without the deleterious effects of over-confluence and lack of media 
resources for cells. These data allow us to extrapolate optimal densities for other cell growth 
areas using the formula: (growth area cm
2
/.32 cm
2
) x 1000 = optimal plating density. 
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Figure 5. Cell viability assay to determine optimal plating density of RKO cells in 96 well 
plates. Cells were plated at different densities and on day 0, 2, 4 and 6, cell viability was 
measured by Cell Titer Glo Luminescent Cell Viability Assay (cell number correlates with 
luminescent output, RLU). 
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Exogenous sCXCL16 does not increase RKO cell proliferation 
 The shedding of cell surface molecules is a regulatory mechanism necessary to mediate 
biological activities such as juxtacrine, autocrine and paracrine signaling and releasing 
cytoplasmic domains for intracellular signaling. CXCL16 recruits CXCR6-expressing CD4
+
 and 
CD8
+
 T cells 
4
, and is associated with increased proliferation of murine astroglial and microglial 
CXCR6-expressing cells
8
. CXCL16 activity occurs with a concentration of 10 ng/mL, as 
measured by chemotaxis of CXCR6 expressing JURKAT cells and CXCR6 expressing CD4
+
, 
CD8
+
, and NKT cells 
3
. To test the effect of CXCL16 on cell proliferation through ligand-
receptor binding, RKO cells were incubated overnight with purchased recombinant human 
CXCL16 (rhCXCL16) at concentrations ranging from 3.125 ng/mL – 100ng/mL and ATP cell 
viability assay was performed. Stimulation of RKO cells with exogenous sCXCL16 in the form 
of recombinant human CXCL16, did not affect the growth rate and viability of the cells (Figure 
6). These data suggest that any effect CXCL16 may have on colon cancer cell proliferation does 
not operate in the receptor-ligand binding mechanisms defining autocrine, paracrine or juxtacrine 
signaling. It is possible that CXCL16 shedding from the cell membrane releases the cytoplasmic 
portion of CXCL16 which is then involved in intracellular signaling. 
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Figure 6. Proliferation measured by ATPase assay of RKO cells after treatment with 
increasing concentrations of exogenous sCXCL16. 
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sCXCL16 increases proliferation and decreases apoptosis compared to cCXCL16 under 
inflammatory conditions 
 We assessed the ability of CXCL16 to affect RKO cell proliferation through intracellular 
signaling. The shedding of cell surface CXCL16 is catalyzed by inflammatory stimulation that 
includes IFNγ, TNFα and IL-1β. Notably, although TNFα and IFNγ alone increase the release of 
sCXCL16, stimulation with these inflammatory cytokines in concert significantly increases 
sCXCL16 concentrations within the same time window 
13
. Shedding of the extracellular portion 
of cell surface molecules is necessary to release the intracellular portion
11
. All cultures were 
treated with the inflammatory cytokine mix containing 1.4 nM rhIFNγ, 2.0 nM rhTNFα and 2.0 
nM rhIL1β. Cell viability, as measured by ATP assay, was assessed every 24 hours for 6 days. 
To further distinguish the shedding of CXCL16 involvement in proliferation from any treatment 
effects attributable to inflammatory stimulation we performed our proliferation studies with the 
additional condition of metalloproteinase inhibition, using the established optimal dose (100 µM) 
of GM6001. Cells releasing sCXCL16 showed greater proliferation than cells retaining 
cCXCL16, although Student’s t-test determined no significant difference, P > 0.05 (Figure 7 A). 
As treatment with increased exogenous sCXCL16 did not increase proliferation in RKO cells, 
our data suggest that CXCL16 plays a role in RKO cell proliferation through intracellular 
signaling.  
To further clarify the association of shedding CXCL16 with proliferation and thereby a 
possible role in tumor growth, we repeated the above experiment using cell cycle analysis as a 
means to measure proliferation and apoptosis. Cell cycle analysis was conducted by flow 
cytometry of PI stained cells. Experimental conditions were compared to control cell cultures 
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grown under non-inflammatory conditions and without metalloproteinase inhibition. Control cell 
cycle analysis is represented in red. Experimental conditions are represented in blue. The portion 
of the cell cycle analysis representing apoptotic cells (0 – 50 on the x-axis), is larger for cells 
maintaining cCXCL16 compared to cells shedding sCXCL16 (Figure 7 C and D, respectively). 
Graphical comparison of the apoptotic indices is represented in Figure 7 B. Cell cycle analysis 
supported our ATP cell viability results and indicated that shedding of CXCL16 from the cell 
membrane of RKO cells was associated with increased proliferation, as shown by an increase in 
the number of cells in the population in G2 (Figure 7 D, portion of histograph with a mean of 100 
on the x-axis). These data suggest that CXCL16 is an important mediator of colon cancer cell 
survival and proliferation through inflammatory signaling pathways. 
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Figure 7. ATPase assay and cell cycle analysis of RKO cells (A) ATPase assay showing 
sCXCL16 is associated with increased RKO cell proliferation compared to cCXCL16. (B) 
Apoptotic index of cell cycle analysis shows that cCXCL16 is associated with increased 
RKO cell death compared to sCXCL16.  (C) Cell cycle analysis of RKO cells grown in 
inflammatory conditions while under GM6001 metalloproteinase inhibition and assayed 
every 24 hours for 6 days after PI staining and measured using flow cytometry. (D) Cell 
cycle analysis of RKO cells grown under inflammatory conditions and assayed every 24 
hours for 6 days after PI staining and measured using flow cytometry. 
Student t-test determined there is no significant difference in experimental conditions for 
proliferation or apoptosis P > 0.05. 
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CONCLUSION 
We have shown that CXCL16 is involved in the proliferation and survival of colorectal cancer 
cells. ADAM10 constitutively cleaves CXCL16, however inflammatory stimulation promotes 
the increased release of sCXCL16 through increased ADAM17 proteolysis. The shedding of cell 
surface CXCL16 is necessary to initiate functional activity related to increased proliferation and 
survival under inflammatory conditions. As increased proliferation and decreased apoptosis is 
not evidenced with increased soluble CXCL16 alone, our data suggest these effects do not result 
from ligand-receptor signaling. CXCL16 is constitutively cleaved by ADAM10, however 
increased cleavage through ADAM17 proteolysis suggests a threshold must be reached to 
overwhelm competing signals or that CXCL16 is only one among other molecules up-regulated 
by inflammatory stimulation working in concert to increase survival and growth. 
 Although it is known that CXCL16 is expressed as a cell surface molecule with an 
extracellular, transmembrane and cytoplasmic domain 
13
, we attempted to detect cell associated 
fragments of CXCL16, specifically by targeting an epitope on the cytoplasmic domain. C-
terminal fragments (CTFs) released after the cell surface portion of CXCL16 is shed are not 
immediately degraded and have been detected in cell lysates 
11
. As cells degrade proteins that are 
no longer useful, we speculated that the CXCL16 CTFs previously identified may function in 
intracellular signaling. Our immunocytochemical analysis revealed that CXCL16 CTFs are 
found in the cytoplasm and associated with the nucleus thereby suggesting further analysis of 
CXCL16 biological activity may be revealing. 
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 ELISA analysis of sCXCL16, after inflammatory stimulation with a cytokine mix 
containing IL-1β, TNFα and IFNγ, determined that inflammation increases CXCL16 shedding, 
and sCXCL16 concentrations increase with continued inflammatory stimulation (Figure 2). It has 
been shown that ADAM10 and ADAM17 are responsible for the shedding of sCXCL16 from the 
cell surface
7, 11, 17, 19
. Using siRNA to knockdown the expression of ADAM10 and ADAM17 
under normal and inflammatory conditions, we found that a decrease in ADAM10 expression to 
less than half of normal expression levels (Figure 4 C) precluded the detection of sCXCL16 
(Figure 4 A), supporting the role of ADAM10 in constitutive cleavage of cell associated 
CXCL16. Knockdown of ADAM17 to less than half of normal expression levels (Figure 4C) did 
not significantly decrease sCXCL16 levels (Figure 4 A), indicating that ADAM17 does not have 
a significant role, if any, in the cleavage of CXCL16 under normal conditions. The knockdown 
experiments under inflammatory stimulation were not conclusive. However, less than 30% 
knockdown of ADAM17 (Figure 4 D) from normal expression levels did result in a slight 
decrease in sCXCL16 (Figure 4 B). These data in conjunction with our ELISA data of increased 
sCXCL16 with inflammatory stimulation, as well as data from previous studies that determined 
ADAM17 cleaves human mesangial cells under inflammatory stimulation
7
, suggest ADAM17 
participate in CXCL16 cleavage in colorectal cancer cells under inflammatory stimulation.  
 Autocrine, paracrine and juxtacrine signaling occurs though ligand-receptor binding. The 
chemotactic and cell adhesion functions of CXCL16 occur through paracrine 
20
 and juxtacine 
signaling 
5, 21, 22
, respectively. We determined that CXCL16 signaling in proliferation does not 
occur through ligand-receptor binding in the human colon cancer cell line RKO. Stimulation of 
RKO with increasing concentrations of sCXCL16 in the form of recombinant human CXCL16 
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(rhCXCl16) did not increase proliferation (Figure 6), although we confirmed the natural ligand, 
CXCR6, is expressed by RKO cells, using RT-PCR and western blot analysis (data not shown). 
However, increased sCXCL16 associated with increased cleavage of cell associated CXCL16 
(cCXCL16), induced by inflammatory stimulation, positively correlated with RKO cell 
proliferation (Figure 7A) and decreased apoptosis (Figure 7 B). The extracellular domain of 
CXCL16, which contains a chemokine domain chemotactic for cells expressing the receptor 
CXCR6 
3, 5, 721
, is shed from the cell membrane due to proteolytic cleavage attributed to the 
metalloproteinases ADAM10 and ADAM17 
7, 8, 11, 17, 19
,as metalloproteinase inhibition prevents 
cCXCL16 proteolysis into sCXCL16. In addition, inhibition of cCXCL16 shedding into 
sCXCL16 with broad spectrum metalloproteinase inhibitors precludes proliferation and the anti-
apoptotic effect of increased sCXCL16 associated with inflammatory stimulation. 
 CXCL16 has been shown to increase proliferation of human umbilical vein endothelial 
cells through ligand receptor binding, although this effect is not as significant when cells are 
stimulated with bFGF
8
. However, knockdown of CXCR6 in human colon carcinoma cells 
showed significantly increased proliferation
12
. While stimulation of wild type colon carcinoma 
cells with soluble CXCL16 showed slight increase in proliferation, pancreatic tumor cells with 
knocked down expression of endogenous CXCL16 showed a 50% increase in proliferation when 
stimulated with exogenous soluble CXCL16
12
. We cannot ignore that these data suggest that 
there is another signaling mechanism, other than CXCL16-CXCR6 axis signaling, by which 
CXCL16 functions to increase proliferation. Using iPSort, we performed an analysis of the 
CXCL16 protein sequence using the FASTA sequence and found a nuclear localization signal 
characterized by a leucine rich repeat (LRR) domain, in the cytoplasmic region. In addition we 
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performed preliminary studies to determine the intercellular localization of any CXCL16 CTF. 
After performing subcellular fractionation on RKO cells in culture, we performed western blot 
analysis using an antibody recognizing an epitope on the cytoplasmic domain of CXCL16. We 
found CXCL16 in the chromatin associated nuclear fraction. Although these data are 
preliminary, they provide insight into the roles of CXCL16 CTF, after further processing. These 
data are also suggestive that CXCL16 may be involved in multiple signaling pathways. CXCL16 
has been found upregulated in brain and pancreatic cancers, where it is not found in normal 
tissue of this type 
8, 12
. In addition to being found upregulated in colon cancer cells
4, 16
, CXCL16 
has been found to be a prognostic factor in prostate cancer 
9
. These data highlight CXCL16 as an 
interesting target for studies in colorectal cancer progression inclusive of cancer progression as a 
whole. We speculate that involvement of CXCL16 on increased proliferation of cancer cells may 
include intercellular signaling by CXCL16 CTFs. Studies to determine the involvement of 
CXCL16 on other proliferative pathways would further elucidate the role of CXCL16 and 
highlight the multifunctional capacity of CXCL16 as a representative of the chemokine family of 
immune molecules, as a whole. 
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